We are focused on chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), as well as immune-driven diseases such as lupus. We follow the science to address tough and complex, unsolved problems - targeting the underlying biology and developing effective new drug modalities and combinations with the ultimate ambition of achieving disease modification and clinical remission.
We are pushing the boundaries of science by targeting underlying disease drivers with new mechanisms and modalities, offering the broadest range of treatments to transform patient outcomes. Our experience developing medicines that treat tens of millions of patients has provided exceptional insights and a deep understanding of the unsolved issues in the management of respiratory and immune-mediated diseases, informing our research.
As the science evolves, we are engaging larger patient cohorts and rich datasets, including the largest database of genomic data in the industry, to improve our understanding of novel imaging biomarkers to assess disease progression and remission. Machine learning and artificial intelligence are accelerating the way we identify novel targets to develop next generation therapeutics. Our patient centric approach to clinical trials is incorporating digital health solutions and transformative study endpoints to enable improved outcomes for patients going beyond symptom control to demonstrate disease modification and remission. And we are changing the way we design and perform our clinical trials to make studies smarter, shorter, and more efficient.
